MX2023005305A - Derivados de 1-(2-(4-ciclopropil-1h-1,2,3-triazol-1-il)acetil)-4-h idroxi-n-(bencil)pirrolidina-2-carboxamida como inhibidores de vhl para el tratamiento de la anemia y el cancer. - Google Patents

Derivados de 1-(2-(4-ciclopropil-1h-1,2,3-triazol-1-il)acetil)-4-h idroxi-n-(bencil)pirrolidina-2-carboxamida como inhibidores de vhl para el tratamiento de la anemia y el cancer.

Info

Publication number
MX2023005305A
MX2023005305A MX2023005305A MX2023005305A MX2023005305A MX 2023005305 A MX2023005305 A MX 2023005305A MX 2023005305 A MX2023005305 A MX 2023005305A MX 2023005305 A MX2023005305 A MX 2023005305A MX 2023005305 A MX2023005305 A MX 2023005305A
Authority
MX
Mexico
Prior art keywords
triazol
cyclopropyl
carboxamide
hydroxy
acetyl
Prior art date
Application number
MX2023005305A
Other languages
English (en)
Spanish (es)
Inventor
Hao Wu
Jakob Fuhrmann
Wayne J Fairbrother
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2023005305A publication Critical patent/MX2023005305A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2023005305A 2020-11-11 2020-11-30 Derivados de 1-(2-(4-ciclopropil-1h-1,2,3-triazol-1-il)acetil)-4-h idroxi-n-(bencil)pirrolidina-2-carboxamida como inhibidores de vhl para el tratamiento de la anemia y el cancer. MX2023005305A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063112609P 2020-11-11 2020-11-11
PCT/US2020/062627 WO2022103411A1 (en) 2020-11-11 2020-11-30 1-(2-(4-cyclopropyl-1h-1,2,3-triazol-1-yl)acetyl)-4-hydroxy-n-(benzyl)pyrrolidin e-2-carboxamide derivatives as vhl inhibitors for the treatment of anemia and cancer

Publications (1)

Publication Number Publication Date
MX2023005305A true MX2023005305A (es) 2023-05-25

Family

ID=73839136

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005305A MX2023005305A (es) 2020-11-11 2020-11-30 Derivados de 1-(2-(4-ciclopropil-1h-1,2,3-triazol-1-il)acetil)-4-h idroxi-n-(bencil)pirrolidina-2-carboxamida como inhibidores de vhl para el tratamiento de la anemia y el cancer.

Country Status (10)

Country Link
US (1) US20230391766A1 (cg-RX-API-DMAC7.html)
EP (1) EP4244218B1 (cg-RX-API-DMAC7.html)
JP (2) JP7654075B2 (cg-RX-API-DMAC7.html)
KR (1) KR102992222B1 (cg-RX-API-DMAC7.html)
CN (1) CN116783183B (cg-RX-API-DMAC7.html)
AU (1) AU2020476996A1 (cg-RX-API-DMAC7.html)
CA (1) CA3197092A1 (cg-RX-API-DMAC7.html)
IL (1) IL302678A (cg-RX-API-DMAC7.html)
MX (1) MX2023005305A (cg-RX-API-DMAC7.html)
WO (1) WO2022103411A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4244219B1 (en) 2020-11-11 2026-06-03 Genentech, Inc. 1-(2-(4-cyclopropyl-1h-1,2,3-triazol-1-yl)acetyl)-4-hydroxypyrrolidine-2-carboxamide derivatives as vhl inhibitors for the treatment of anemia
WO2023220237A1 (en) * 2022-05-11 2023-11-16 Genentech, Inc. Benzothiazole compounds as vhl ligands
WO2025162250A1 (zh) * 2024-02-04 2025-08-07 贝达药业股份有限公司 取代的三环化合物及其用途
WO2025228305A1 (zh) * 2024-04-28 2025-11-06 中国科学院上海药物研究所 一种蛋白降解剂缀合物及其偶联物
WO2026012475A1 (en) * 2024-07-12 2026-01-15 Ascentage Pharma (Suzhou) Co., Ltd. Vhl ligands and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
KR102438072B1 (ko) * 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
WO2013106646A2 (en) * 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
GB2554071A (en) * 2016-09-14 2018-03-28 Univ Dundee Small molecules
CN110573507B (zh) * 2017-04-14 2023-11-14 邓迪大学 小分子
US11547759B2 (en) * 2019-01-30 2023-01-10 Montelino Therapeutics, Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor

Also Published As

Publication number Publication date
US20230391766A1 (en) 2023-12-07
JP2023549187A (ja) 2023-11-22
KR102992222B1 (ko) 2026-07-16
CA3197092A1 (en) 2022-05-19
EP4244218A1 (en) 2023-09-20
CN116783183B (zh) 2026-03-20
IL302678A (en) 2023-07-01
JP7654075B2 (ja) 2025-03-31
EP4244218C0 (en) 2026-07-08
EP4244218B1 (en) 2026-07-08
AU2020476996A1 (en) 2023-06-29
WO2022103411A1 (en) 2022-05-19
CN116783183A (zh) 2023-09-19
KR20230106637A (ko) 2023-07-13
JP2025063287A (ja) 2025-04-15

Similar Documents

Publication Publication Date Title
PE20210642A1 (es) Inhibidores de pd-1/pd-l1
NZ594981A (en) Hepatitis c virus inhibitors
PE20091673A1 (es) Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilizacion
UY24434A1 (es) Nuevos imidazoles sustituidos con cicloalquilo
CY1113547T1 (el) Διαδικασια συνθεσης ενωσεων χρησιμων στην αντιμετωπιση της ηπατιτιδας c
EA201000196A1 (ru) Кристаллическая форма дигидрохлорида метил((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((метоксикарбонил)амино)-3-метилбутаноил)-2-пирролидинил)-1н-имидазол-5-ил)-4-бифенилил)-1н-имидазол-2-ил)-1-пирролидинил)карбонил)-2-метилпропил)карбамата
NZ594068A (en) Substituted benzimidazole compounds as hepatitis c virus inhibitors
NZ598125A (en) Apaf-1 inhibitor compounds
PE20142185A1 (es) Pirrolidina-2-carboxamidas sustituidas
NZ710567A (en) Antiviral compounds
JP2016504378A5 (cg-RX-API-DMAC7.html)
NZ595168A (en) Hepatitis c virus inhibitors
CY1123661T1 (el) Κρυσταλλικη μορφη ενος αναστολεα της mdm2
PH12019501786A1 (en) Hiv inhibitor compound
RU2014152276A (ru) Замещенные пирролидины в качестве ингибиторов фактора xia для лечения тромбоэмболических заболеваний
EA201170617A1 (ru) Пиразолиламинопиридины в качестве ингибиторов fak
NZ595073A (en) Proline derivatives as cathepsin inhibitors
NZ591449A (en) Picolinamide derivatives as kinase inhibitors
NZ591427A (en) P38 map kinase inhibitors
NZ594163A (en) Pyranose derivatives of pestcidal 1,2,4-triazoles
EA200802329A1 (ru) Производные триазола ii
FI3658141T3 (fi) Patologisten tilojen hoitaminen suoralla tai epäsuoralla siralfa-cd47-vuorovaikutukseen kohdentamisella
NZ611528A (en) Neprilysin inhibitors
AR057109A1 (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis
AR112284A1 (es) Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico